Yeah that’s a good point. Our trial design seems a lot smarter. The other thing which I keep coming back to is the eligibility criteria for starting uPCR. DMX has shown in our previous trials to have a more significant reduction on patients with higher starting uPCR. And obviously a higher reduction in uPCR leads to more improvement to kidney function and reduction of eGFR slope. So this all bodes well for us hopefully.
Note - a big disclaimer here for anyone that read my earlier posts - but I think for some reason I referred to uPCR as “uPVC”. Not sure if this was auto spell correct or if I’m dyslexic! But please just substitute these terms when reading….hopefully everyone knew what I meant.
Dimerix (ASX: DXB) Discussion Thread, page-151
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.0¢ |
Change
0.030(7.69%) |
Mkt cap ! $217.1M | |||
| Open | High | Low | Value | Volume |
| 39.5¢ | 42.0¢ | 38.8¢ | $1.619M | 3.997M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 116189 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 266756 | 6 |
View Market Depth
| Last trade - 11.40am 29/05/2024 (20 minute delay) ? |
|
|||||
|
Last
41.5¢ |
Change
0.030 ( 6.03 %) |
||||
| Open | High | Low | Volume | ||
| 39.5¢ | 41.5¢ | 39.0¢ | 2267753 | ||
| Last updated 11.58am 29/05/2024 ? | |||||
| DXB (ASX) Chart |